Moxifloxacin Tad

Moxifloxacin, the active ingredient in Moxifloxacin Tad, is a fluoroquinolone presented as an injectable solution for intravenous use. It is indicated for the treatment of serious bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, exacerbations of chronic bronchitis, and skin and soft‑tissue infections in adult patients.

GNH USA supplies Moxifloxacin Tad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Moxifloxacin is a broad‑spectrum fluoroquinolone antibiotic used to treat bacterial infections in the respiratory and skin compartments.

- Community‑acquired bacterial pneumonia: effective bacterial eradication leading to clinical recovery. - Acute bacterial sinusitis: rapid resolution of sinus infection symptoms. - Acute bacterial exacerbation of chronic bronchitis: reduction of bacterial load and improvement of airflow. - Skin and soft tissue infections: clearance of pathogenic bacteria and promotion of wound healing.

Moxifloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Dizziness: occasional vertigo or light‑headedness. - Rash: mild skin erythema or pruritus. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, may occur without warning. - QT interval prolongation: risk of cardiac arrhythmias. - Severe allergic reactions: anaphylaxis, angioedema. - Clostridioides difficile infection: colitis with watery diarrhea. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin detachment. - Hepatic failure: rare but potentially life‑threatening liver injury.

Before initiating therapy with Moxifloxacin Tad, clinicians should consider several safety aspects.

- Assess renal function: adjust therapy in patients with impaired clearance. - Monitor cardiac QT interval: avoid use with other QT‑prolonging agents. - Evaluate for tendon disorders: discontinue if tendon pain or inflammation occurs. - Avoid in known hypersensitivity: do not administer to patients with previous fluoroquinolone reactions. - Use with caution in pregnancy: safety category is unknown, weigh benefits against risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin Tad can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - QT‑prolonging agents (e.g., amiodarone, sotalol): increased risk of arrhythmia. - Warfarin: enhanced anticoagulant effect, may raise INR. - Theophylline: elevated plasma concentrations, risk of toxicity.

Moderate Interactions (Monitor Closely): - Antacids or sucralfate: may reduce moxifloxacin absorption. - Systemic corticosteroids: heightened risk of tendon rupture. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): additive central nervous system effects.